Effects of neuromuscular electrical stimulation on pulmonary alveola and cytokines in chronic obstructive pulmonary disease (COPD) and skeletal muscle atrophy model mice.
Hiroshi Maruoka, Ken-Ichi Tanaka, Masaaki Takayanagi and 1 others
PMID 33519066WHAT IT FOUND
In mice with lung disease and muscle loss, electrical muscle stimulation lowered some lung inflammation markers but did not protect muscle strength or reverse alveolar damage.
These molecular changes have not been tested in humans and should not guide clinical practice.
Key findings
01Neuromuscular electrical stimulation significantly reduced IL-6 levels in the lungs and MuRF1 expression in skeletal muscle compared to the untreated group.
02Muscle strength decreased significantly in both the stimulated and unstimulated groups, meaning the treatment did not prevent strength loss.
03Alveolar destruction, measured by mean linear intercept, increased significantly in both disease groups with no difference between those receiving stimulation and those who did not.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study was conducted entirely in mice, not humans. The COPD model was induced by injecting tobacco solution into the trachea and suspending the hindlimbs, which does not replicate the natural progression of human COPD. Muscle strength declined in both the treatment and control disease groups, suggesting the stimulation protocol failed to preserve function in this specific model. Structural lung damage (alveolar destruction) was not improved by the intervention.
Declared interests
The study was supported by a JSPS KAKENHI grant. The authors declared no conflicts of interest.
The easy way to misread this
Do not interpret the reduction in inflammatory markers as evidence that electrical stimulation improves lung function or muscle strength in patients. In this animal model, the treatment failed to prevent muscle weakness or reverse alveolar damage, and these molecular changes have not been shown to translate to clinical benefit in humans.